Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Heres

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Schizophrenia Bulletin Open|January 26, 2026
Attitudes Driving Regional Differences in Long-Acting Injectable Antipsychotic Utilization for Schizophrenia among Healthcare Professionals, Patients, and Caregivers (ADVANCE): Results from a Multinational Survey StudyKelli R Franzenburg, Rolf Hansen, Mark Suett, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 11, 2020
Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohortLinda Levi, Mor Bar Haim, Shimon Burshtein, et al.
The Cochrane Database of Systematic Reviews|August 26, 2020
Maintenance treatment with antipsychotic drugs for schizophreniaAnna Ceraso, Jessie Jingxia Lin, Johannes Schneider-Thoma, et al.
Frontiers in Psychiatry|December 25, 2025
Experiences and perceptions of patients, caregivers, and healthcare professionals with long-acting injectable antipsychotics for the treatment of schizophrenia: qualitative results from the multinational ADVANCE studyKelli R Franzenburg, Rolf Hansen, Mark Suett, et al.
Current Medical Research and Opinion|September 26, 2017
Development of a stated-preference instrument to prioritize treatment goals in recent onset schizophreniaKathleen Beusterien, Elcie Chan, Pedro Such, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 8, 2018
Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) studyPierre-Michel Llorca, Julio Bobes, W Wolfgang Fleischhacker, et al.
BMC Psychiatry|June 17, 2022
Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophreniaSpyridon Siafis, Nicola Bursch, Katharina Müller, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|January 9, 2023
Supporting return to work after psychiatric hospitalization-A cluster randomized study (RETURN-study)Johannes Hamann, Anne Lang, Lina Riedl, et al.
Focus (American Psychiatric Publishing)|January 31, 2020
The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching AntipsychoticsStefan Leucht, Inge Winter-van Rossum, Stephan Heres, et al.
Schizophrenia Bulletin|March 20, 2015
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychoticsStefan Leucht, Inge Winter-van Rossum, Stephan Heres, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Schizophrenia Bulletin Open|January 26, 2026
Attitudes Driving Regional Differences in Long-Acting Injectable Antipsychotic Utilization for Schizophrenia among Healthcare Professionals, Patients, and Caregivers (ADVANCE): Results from a Multinational Survey StudyKelli R Franzenburg, Rolf Hansen, Mark Suett, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 11, 2020
Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohortLinda Levi, Mor Bar Haim, Shimon Burshtein, et al.
The Cochrane Database of Systematic Reviews|August 26, 2020
Maintenance treatment with antipsychotic drugs for schizophreniaAnna Ceraso, Jessie Jingxia Lin, Johannes Schneider-Thoma, et al.
Frontiers in Psychiatry|December 25, 2025
Experiences and perceptions of patients, caregivers, and healthcare professionals with long-acting injectable antipsychotics for the treatment of schizophrenia: qualitative results from the multinational ADVANCE studyKelli R Franzenburg, Rolf Hansen, Mark Suett, et al.
Current Medical Research and Opinion|September 26, 2017
Development of a stated-preference instrument to prioritize treatment goals in recent onset schizophreniaKathleen Beusterien, Elcie Chan, Pedro Such, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 8, 2018
Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) studyPierre-Michel Llorca, Julio Bobes, W Wolfgang Fleischhacker, et al.
BMC Psychiatry|June 17, 2022
Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophreniaSpyridon Siafis, Nicola Bursch, Katharina Müller, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|January 9, 2023
Supporting return to work after psychiatric hospitalization-A cluster randomized study (RETURN-study)Johannes Hamann, Anne Lang, Lina Riedl, et al.
Focus (American Psychiatric Publishing)|January 31, 2020
The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching AntipsychoticsStefan Leucht, Inge Winter-van Rossum, Stephan Heres, et al.
Schizophrenia Bulletin|March 20, 2015
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychoticsStefan Leucht, Inge Winter-van Rossum, Stephan Heres, et al.
Pageof 9